Free Trial

EKF Diagnostics (LON:EKF) Shares Pass Below 200 Day Moving Average - Here's What Happened

EKF Diagnostics logo with Medical background
Image from MarketBeat Media, LLC.

Key Points

  • EKF Diagnostics shares fell below their 200-day moving average, trading as low as GBX 24.10 versus the 200-day average of GBX 25.93, on a volume of 195,216 shares.
  • The company has a market cap of £103.89 million and a high P/E of 51.28; it reported quarterly EPS of GBX 0.47 and sell-side analysts expect roughly 2.30 EPS for the current year.
  • EKF is an AIM-listed global diagnostics group focused on point-of-care hematology and diabetes analysers and life-sciences enzyme manufacture, with five manufacturing sites and sales into over 120 countries.
  • Interested in EKF Diagnostics? Here are five stocks we like better.

EKF Diagnostics Holdings plc (LON:EKF - Get Free Report) shares crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of GBX 25.93 and traded as low as GBX 24.10. EKF Diagnostics shares last traded at GBX 24.10, with a volume of 195,216 shares traded.

EKF Diagnostics Price Performance

The company has a market cap of £103.89 million, a price-to-earnings ratio of 51.28 and a beta of 0.29. The stock has a fifty day moving average price of GBX 25 and a two-hundred day moving average price of GBX 25.93. The company has a quick ratio of 1.77, a current ratio of 4.16 and a debt-to-equity ratio of 2.01.

EKF Diagnostics (LON:EKF - Get Free Report) last issued its earnings results on Tuesday, March 24th. The company reported GBX 0.47 earnings per share for the quarter. EKF Diagnostics had a return on equity of 3.01% and a net margin of 4.12%. As a group, sell-side analysts expect that EKF Diagnostics Holdings plc will post 2.2987842 EPS for the current year.

EKF Diagnostics Company Profile

(Get Free Report)

EKF is an AIM-listed global diagnostics business focussed on: ● Point-of-Care analysers in the key areas of Hematology and Diabetes ● Life Sciences services provide specialist manufacture of enzymes and custom products for use in diagnostic, food and industrial applications. EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.

Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in EKF Diagnostics Right Now?

Before you consider EKF Diagnostics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and EKF Diagnostics wasn't on the list.

While EKF Diagnostics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy And Hold Forever Cover

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines